AZD1613
Monoclonal antibody
Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (2)
What this study did
What this study did
Competitive landscape
This drug's own stage for Autosomal Dominant Polycystic Kidney Disease: Phase 1. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| AZD1613: this drug | Phase 1 | Monoclonal antibody | PAPP-A | not yet graded | No reviewed efficacy summary in this indication | |
| Tolvaptan (Jynarque) | Approved | Small molecule | Vasopressin V2 receptor | Partial signal | NCT02160145: Annualized change in eGFR (REPRISE trial): -2.34 mL/min/1.73m2/year tolvaptan vs -3.61 mL/min/1.73m2/year placebo; difference 1.27 mL/min/1.73m2/year (95% CI 0.86-1.68), 35% reduction in decline, P<0.001 NCT00428948: Total kidney volume growth over 36 months: tolvaptan 2.78% per year vs placebo 5.61% per year; difference -2.71 percentage points per year (95% CI -3.27 to -2.15), p<0.0001 (n=819 and 458 analysed) (CT.gov posted results). | |
| VX-407 | Phase 2 | Small molecule | Polycystin-1 (PKD1 variants) | not yet graded | No reviewed efficacy summary in this indication | |
| GSK4771261 | Phase 1 | Monoclonal antibody | — | not yet graded | No reviewed efficacy summary in this indication | |
| Farabursen | —(overall) | RNA / oligonucleotide | miR-17 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow AZD1613 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.